Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 344

Similar articles for PubMed (Select 21787203)

1.

Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.

Sola-Ortigosa J, Sánchez-Regaña M, Umbert-Millet P.

J Dermatolog Treat. 2012 Jun;23(3):203-7. doi: 10.3109/09546634.2010.519376. Epub 2011 Jul 25.

PMID:
21787203
2.

Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.

Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S.

J Am Acad Dermatol. 2007 Aug;57(2):269-75. Epub 2007 Jun 18.

PMID:
17574299
3.

Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.

Ortonne JP, Chimenti S, Reich K, Gniadecki R, Sprøgel P, Unnebrink K, Kupper H, Goldblum O, Thaçi D.

J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1012-20. doi: 10.1111/j.1468-3083.2010.03944.x. Epub 2011 Jan 9.

PMID:
21214631
4.
5.
6.

Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.

Kyriakou A, Patsatsi A, Sotiriadis D.

J Dermatolog Treat. 2013 Jun;24(3):162-8. doi: 10.3109/09546634.2011.646939. Epub 2012 Jan 4.

PMID:
22136334
7.

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study.

Asahina A, Nakagawa H, Etoh T, Ohtsuki M; Adalimumab M04-688 Study Group.

J Dermatol. 2010 Apr;37(4):299-310. doi: 10.1111/j.1346-8138.2009.00748.x.

PMID:
20507398
8.

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.

Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.

Am J Clin Dermatol. 2011 Feb 1;12(1):51-62. doi: 10.2165/11530640-000000000-00000.

PMID:
21110526
9.

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.

J Dermatolog Treat. 2007;18(6):341-50.

PMID:
18058494
10.

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A; CHAMPION Study Investigators.

Br J Dermatol. 2008 Mar;158(3):558-66. Epub 2007 Nov 28.

PMID:
18047523
11.

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K.

J Am Acad Dermatol. 2008 Jan;58(1):106-15. Epub 2007 Oct 23.

PMID:
17936411
12.

Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.

Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M, Perricone R, Chimenti S, Chimenti MS.

Dermatology. 2012;225(4):312-9. doi: 10.1159/000345623. Epub 2012 Dec 28.

PMID:
23295383
13.

Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.

Paul C, van de Kerkhof P, Puig L, Unnebrink K, Goldblum O, Thaçi D.

Eur J Dermatol. 2012 Nov-Dec;22(6):762-9. doi: 10.1684/ejd.2012.1863.

PMID:
23178916
14.

Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.

Noda S, Mizuno K, Adachi M.

J Dermatol. 2012 Mar;39(3):265-8. doi: 10.1111/j.1346-8138.2011.01312.x. Epub 2011 Nov 29.

PMID:
22126280
15.

Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.

Ryan C, Kirby B, Collins P, Rogers S.

Clin Exp Dermatol. 2009 Oct;34(7):784-8. doi: 10.1111/j.1365-2230.2008.03161.x. Epub 2009 Apr 27.

PMID:
19438535
17.
18.

Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.

Martyn-Simmons CL, Green L, Ash G, Groves RW, Smith CH, Barker JN.

J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7. doi: 10.1111/j.1468-3083.2009.03325.x. Epub 2009 Jul 1.

PMID:
19573024
19.

Cost effectiveness of biologic therapies for plaque psoriasis.

Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR.

Am J Clin Dermatol. 2013 Aug;14(4):315-26. doi: 10.1007/s40257-013-0030-z. Review.

PMID:
23696234
20.

Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept.

Bissonnette R, Bolduc C, Poulin Y, Guenther L, Lynde CW, Maari C.

J Am Acad Dermatol. 2010 Aug;63(2):228-34. doi: 10.1016/j.jaad.2009.08.040. Epub 2010 May 21.

PMID:
20494479
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk